CN113713083A - Pharmaceutical composition for treating alopecia - Google Patents
Pharmaceutical composition for treating alopecia Download PDFInfo
- Publication number
- CN113713083A CN113713083A CN202010446803.5A CN202010446803A CN113713083A CN 113713083 A CN113713083 A CN 113713083A CN 202010446803 A CN202010446803 A CN 202010446803A CN 113713083 A CN113713083 A CN 113713083A
- Authority
- CN
- China
- Prior art keywords
- alopecia
- tofacitinib
- pharmaceutical composition
- treating
- hair
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000004384 Alopecia Diseases 0.000 title claims abstract description 43
- 231100000360 alopecia Toxicity 0.000 title claims abstract description 37
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 14
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims abstract description 17
- 108010036949 Cyclosporine Proteins 0.000 claims abstract description 17
- 239000004012 Tofacitinib Substances 0.000 claims abstract description 13
- 229960001350 tofacitinib Drugs 0.000 claims abstract description 13
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 claims abstract description 13
- 239000004480 active ingredient Substances 0.000 claims abstract description 10
- 210000004209 hair Anatomy 0.000 claims abstract description 9
- 229930105110 Cyclosporin A Natural products 0.000 claims abstract description 7
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
- 229960001265 ciclosporin Drugs 0.000 claims description 15
- 238000011282 treatment Methods 0.000 claims description 7
- 210000003780 hair follicle Anatomy 0.000 claims description 6
- 239000012458 free base Substances 0.000 claims description 5
- 230000003676 hair loss Effects 0.000 claims description 5
- 208000024963 hair loss Diseases 0.000 claims description 4
- 239000011159 matrix material Substances 0.000 claims description 4
- 150000004940 Tofacitinib derivatives Chemical class 0.000 claims description 3
- 206010068168 androgenetic alopecia Diseases 0.000 claims description 2
- 201000002996 androgenic alopecia Diseases 0.000 claims description 2
- 239000003125 aqueous solvent Substances 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 230000003797 telogen phase Effects 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 2
- 230000037390 scarring Effects 0.000 claims 2
- 206010001766 Alopecia totalis Diseases 0.000 claims 1
- 206010001767 Alopecia universalis Diseases 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- 208000003024 Diffuse alopecia Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 201000009495 Hypotrichosis Diseases 0.000 claims 1
- 208000006450 Hypotrichosis simplex Diseases 0.000 claims 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims 1
- 206010043866 Tinea capitis Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 208000004631 alopecia areata Diseases 0.000 claims 1
- 208000032775 alopecia universalis congenita Diseases 0.000 claims 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
- 208000022605 chemotherapy-induced alopecia Diseases 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 201000011486 lichen planus Diseases 0.000 claims 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 1
- 239000011976 maleic acid Substances 0.000 claims 1
- 229910017604 nitric acid Inorganic materials 0.000 claims 1
- 239000011975 tartaric acid Substances 0.000 claims 1
- 235000002906 tartaric acid Nutrition 0.000 claims 1
- 201000001297 telogen effluvium Diseases 0.000 claims 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 239000000203 mixture Substances 0.000 abstract description 4
- 239000004615 ingredient Substances 0.000 abstract description 2
- 230000003648 hair appearance Effects 0.000 abstract 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 30
- SYIKUFDOYJFGBQ-YLAFAASESA-N tofacitinib citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 SYIKUFDOYJFGBQ-YLAFAASESA-N 0.000 description 12
- 229960004247 tofacitinib citrate Drugs 0.000 description 12
- 229930182912 cyclosporin Natural products 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 5
- 229960005323 phenoxyethanol Drugs 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000002453 shampoo Substances 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000000442 hair follicle cell Anatomy 0.000 description 2
- 230000003779 hair growth Effects 0.000 description 2
- 230000003660 hair regeneration Effects 0.000 description 2
- 229960003632 minoxidil Drugs 0.000 description 2
- 210000002464 muscle smooth vascular Anatomy 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 229940122245 Janus kinase inhibitor Drugs 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000003656 anti-hair-loss Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 208000024349 endocrine alopecia Diseases 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000003659 hair regrowth Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- YFDSDPIBEUFTMI-UHFFFAOYSA-N tribromoethanol Chemical compound OCC(Br)(Br)Br YFDSDPIBEUFTMI-UHFFFAOYSA-N 0.000 description 1
- 229950004616 tribromoethanol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
Abstract
The invention relates to a pharmaceutical composition for treating alopecia, which is used as a pharmaceutical preparation for treating related alopecia diseases. The main active ingredients of the composition are tofacitinib and cyclosporine A, the composition has better effect and quick response time than the single ingredient, and the grown hair is the same as the normal hair and has harder hair quality.
Description
Technical Field
The invention relates to a pharmaceutical composition for treating alopecia, which is used as a pharmaceutical preparation for treating related alopecia diseases.
Background
Alopecia is a common dermatological disease, and with the increasing pace of life and work, health indexes issued by relevant national departments show that the incidence rate is as high as 30%. The causes of alopecia are many, and can be generally classified into androgenetic alopecia, neurogenic alopecia, endocrine alopecia, symptomatic alopecia, and the like. The existing effective methods for treating alopecia and promoting hair regeneration are very limited, and the common methods are clinical medication and physical surgery hair transplantation. These treatments are not only expensive but also inconvenient to the patient.
The effective components for treating alopecia are blended into the shampoo used in daily life to treat alopecia and promote hair growth, and the shampoo is convenient to use and is economical and practical. Patent CN107847428A discloses tofacitinib citrate as a medicine for treating alopecia, but the effect of the tofacitinib citrate as a single component on treating alopecia compared with a test has a certain effect, but is not very obvious; patent 201510190767.X discloses the preparation of shampoo for preventing alopecia and promoting hair growth by using gamma-polyglutamic acid with ultrahigh molecular weight as an effective ingredient; although these patent publications have a certain anti-hair loss effect, the effect of promoting hair regrowth is not yet very significant. Patent CN106138058A discloses a composition of tofacitinib and minoxidil, which has a good effect, but because of the large side effect of minoxidil, the clinical application is limited.
Disclosure of Invention
Based on the above problems, the present invention aims to provide a pharmaceutical composition for treating alopecia.
The technical scheme of the invention is as follows:
a pharmaceutical composition for treating alopecia, characterized in that the active ingredients thereof are pharmaceutical preparations consisting of tofacitinib and cyclosporin A; wherein tofacitinib comprises tofacitinib free base and/or tofacitinib salt.
The pharmaceutical composition for treating alopecia according to claim 1, wherein the mass percentage of one of tofacitinib free base and its salt to cyclosporin A in the active ingredient is 10: 90 to 90: 10.
The pharmaceutical composition for treating alopecia according to claim 1 or 2, further comprising a carrier matrix, wherein the mass percentage of the active ingredient to the carrier medium is 1: 99-15: 85, and the carrier matrix comprises one or more of an aqueous solvent, an alcohol solvent or a hair washing and caring product.
The pharmaceutical combination for treating alopecia according to claim 3, wherein the mass percentage of the active ingredients to the carrier medium is 3: 97-8: 92.
The pharmaceutical composition for treating alopecia according to claim 3, wherein the hair care product comprises one or more of cream and spray.
The pharmaceutical combination for the treatment of alopecia according to claim 3, characterized in that the treatment occurs when the hair follicles are in the mid-telogen phase or in the late telogen phase
The active ingredients of the pharmaceutical composition for treating alopecia provided by the invention comprise tofacitinib and cyclosporine A, wherein the tofacitinib is a JAK inhibitor and can be selectively combined with the specific protein active site of target cells (such as dermis, epidermis, dermal papilla cells or hair follicle cells) to inhibit the transmission of cell pathway signals and the synthesis of characteristic cytokines, thereby reducing symptoms related to hair loss diseases; cyclosporin A is a potassium ion channel opener, can directly relax vascular smooth muscle, has strong arteriolar dilatation effect, reduces peripheral resistance, promotes the growth of hair follicle cells, and regenerates hair; the combination of the two substances can act on target protein of target cells and vascular smooth muscle synergistically, and the effect of remarkably promoting hair regeneration is achieved by inhibiting the synthesis of cytokines and accelerating blood circulation.
Detailed Description
The present invention is further illustrated by the following examples.
Example 1
Prescription: 5g of tofacitinib citrate, 10g of cyclosporine, 100ml of propylene glycol, 300ml of ethanol and 1g of phenoxyethanol, and adding water to 1000ml, wherein the operation steps are as follows: weighing tofacitinib citrate and cyclosporine with the prescription amount, adding propylene glycol and ethanol with the prescription amount, stirring and completely dissolving, and adding purified water to 1000 ml.
Example 2
Prescription: 10g of tofacitinib citrate, 10g of cyclosporine, 100ml of propylene glycol, 300ml of ethanol and 1g of phenoxyethanol, and adding water to 1000ml, wherein the operation steps are as follows: weighing tofacitinib citrate and cyclosporine with the prescription amount, adding propylene glycol and ethanol with the prescription amount, stirring and completely dissolving, and adding purified water to 1000 ml.
Example 3
Prescription: 15g of tofacitinib citrate, 10g of cyclosporine, 100ml of propylene glycol, 300ml of ethanol and 1g of phenoxyethanol, and adding water to 1000ml, wherein the operation steps are as follows: weighing tofacitinib citrate and cyclosporine with the prescription amount, adding propylene glycol and ethanol with the prescription amount, stirring and completely dissolving, and adding purified water to 1000ml
Example 4
Prescription: 10g of tofacitinib citrate, 15g of cyclosporine, 100ml of propylene glycol, 300ml of ethanol and 1g of phenoxyethanol, and adding water to 1000ml, wherein the operation steps are as follows: weighing tofacitinib citrate and cyclosporine with the prescription amount, adding propylene glycol and ethanol with the prescription amount, stirring and completely dissolving, and adding purified water to 1000ml
Example 5
Prescription: 10g of tofacitinib citrate, 20g of cyclosporine, 100ml of propylene glycol, 300ml of ethanol and 1g of phenoxyethanol, and adding water to 1000ml, wherein the operation steps are as follows: weighing tofacitinib citrate and cyclosporine according to the prescription amount, adding propylene glycol and ethanol according to the prescription amount, stirring and completely dissolving, and adding purified water to 1000m
Example 6
Subject: the 6-week-old C57 male mice were divided into a group a and a group B, wherein the group a was administered with the formulation prepared in example 1, the group B was a control group administered with only the vehicle blank, and 5 mice per group were selected as experimental subjects.
The operation process is as follows: c57 mice were anesthetized with tribromoethanol and then smeared with molten paraffin on their backs; after the paraffin is solidified, the hairs on the back are torn off to expose the skin; on the ninth day after plucking, cyclophosphamide (20. mu.g/g) was injected; the drug is smeared on the skin of the back of the mouse for 1 time/2 day from the day of administration; smearing 40 mul of blank auxiliary materials on the left side and 40 mul of medicine-containing preparation on the right side; mice were sacrificed on day 21, dorsal harvest, sectioning, HE staining, and mounting.
The experimental results are as follows: compare the number of hair follicles in group A and group B in the same high power or low power field. The hair follicles on the skin on the back of the mouse are dyed blue, and under the same area, the blue small spots in the group A are more obvious than those in the group B, which shows that the preparation containing the embodiment has obvious hair follicle proliferation promoting effect on the mouse and has obvious improvement effect on common hair loss, radiotherapy and chemotherapy hair loss and hair follicle injury.
Claims (8)
1. A pharmaceutical composition for treating alopecia, characterized in that the active ingredients thereof are pharmaceutical preparations consisting of tofacitinib and cyclosporin A; wherein tofacitinib comprises tofacitinib free base and/or tofacitinib salt.
2. The pharmaceutical composition for treating alopecia according to claim 1, wherein the mass percentage of one of tofacitinib free base and its salt to cyclosporin A in the active ingredient is 10: 90-90: 10.
3. The pharmaceutical composition for treating alopecia according to claim 1 or 2, further comprising a carrier matrix, wherein the mass percentage of the active ingredient to the carrier medium is 1: 99-15: 85, and the carrier matrix comprises one or more of an aqueous solvent, an alcohol solvent or a hair washing and caring product.
4. The pharmaceutical combination for treating alopecia according to claim 3, wherein the mass percentage of the active ingredients to the carrier medium is 3: 97-8: 92.
5. The pharmaceutical composition for treating alopecia according to claim 3, wherein the hair care product comprises one or more of cream and spray.
6. The pharmaceutical combination for the treatment of alopecia according to claim 3, characterized in that the treatment occurs when the hair follicles are in mid-telogen phase or late telogen phase.
7. The pharmaceutical combination for the treatment of alopecia according to claim 3, characterized in that the symptoms of alopecia are treated such as: androgenetic alopecia, telogen effluvium, alopecia areata, tinea capitis, alopecia totalis, hypotrichosis, hereditary hypotrichosis simplex, frontal fibrosis alopecia, cicatricial alopecia, lichen planus, alopecia annulata, scarring alopecia, non-scarring alopecia, alopecia universalis, or chemotherapy-induced alopecia.
8. The pharmaceutical combination for the treatment of hair loss according to claim 1, wherein the tofacitinib salt is obtained after reaction of tofacitinib free base with one of the following acids: maleic acid, tartaric acid, citric acid, sulfuric acid, phosphoric acid, nitric acid and hydrochloric acid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010446803.5A CN113713083A (en) | 2020-05-25 | 2020-05-25 | Pharmaceutical composition for treating alopecia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010446803.5A CN113713083A (en) | 2020-05-25 | 2020-05-25 | Pharmaceutical composition for treating alopecia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113713083A true CN113713083A (en) | 2021-11-30 |
Family
ID=78671517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010446803.5A Pending CN113713083A (en) | 2020-05-25 | 2020-05-25 | Pharmaceutical composition for treating alopecia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113713083A (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1373651A (en) * | 1999-11-19 | 2002-10-09 | Lg生活健康株式会社 | Use of monimmunosuppressive cyclosporin A derivative for hair growth |
| CN1726902A (en) * | 2005-07-26 | 2006-02-01 | 钟健琳 | Combined formula and application of agent for stimulating growth of hair, and application |
| CN1738591A (en) * | 2002-11-12 | 2006-02-22 | 沃纳-兰伯特公司 | Method of stimulating hair growth using benzopyrans |
| US20120277247A1 (en) * | 2011-04-28 | 2012-11-01 | Christel Jeanne Marie Menet | Novel compound useful for the treatment of degenerative and inflammatory diseases |
| CN106138058A (en) * | 2016-08-15 | 2016-11-23 | 颜晓丽 | A kind of hair growth inducers |
| CN110300586A (en) * | 2017-02-17 | 2019-10-01 | 加拉帕戈斯股份有限公司 | Anti-inflammatory composition comprising IRAK and JAK inhibitor |
| US20200147116A1 (en) * | 2017-01-21 | 2020-05-14 | Ningbo Zhiming Biotechnology Co., Ltd. | Use of Paeoniflorin-6'-O-benzenesulfonate in treatment of Sjögren's syndrome |
-
2020
- 2020-05-25 CN CN202010446803.5A patent/CN113713083A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1373651A (en) * | 1999-11-19 | 2002-10-09 | Lg生活健康株式会社 | Use of monimmunosuppressive cyclosporin A derivative for hair growth |
| CN1738591A (en) * | 2002-11-12 | 2006-02-22 | 沃纳-兰伯特公司 | Method of stimulating hair growth using benzopyrans |
| CN1726902A (en) * | 2005-07-26 | 2006-02-01 | 钟健琳 | Combined formula and application of agent for stimulating growth of hair, and application |
| US20120277247A1 (en) * | 2011-04-28 | 2012-11-01 | Christel Jeanne Marie Menet | Novel compound useful for the treatment of degenerative and inflammatory diseases |
| CN106138058A (en) * | 2016-08-15 | 2016-11-23 | 颜晓丽 | A kind of hair growth inducers |
| US20200147116A1 (en) * | 2017-01-21 | 2020-05-14 | Ningbo Zhiming Biotechnology Co., Ltd. | Use of Paeoniflorin-6'-O-benzenesulfonate in treatment of Sjögren's syndrome |
| CN110300586A (en) * | 2017-02-17 | 2019-10-01 | 加拉帕戈斯股份有限公司 | Anti-inflammatory composition comprising IRAK and JAK inhibitor |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2498783B1 (en) | Compositions and methods for stimulating hair growth | |
| KR102102578B1 (en) | Cosmetic composition for strengthening hair bulb comprising mixture of 18β-Glycyrrhetic acid, D-panthenol and Menthol as effective component | |
| KR102023021B1 (en) | Cosmetic or pharmaceutical composition for promoting hair growth containing Hydroxydecanoic acid | |
| EP0659080B1 (en) | Method for the treatment of hair loss | |
| CN113713083A (en) | Pharmaceutical composition for treating alopecia | |
| KR101670865B1 (en) | Cosmetic or pharmaceutical composition for promoting hair growth containing Sinomenine Hydrochloride | |
| KR101618349B1 (en) | Cosmetic or pharmaceutical composition for promoting hair growth containing Dehydroandrographolide | |
| JP5902184B2 (en) | Hair growth promoter, eyelash and eyebrow growth promoter, and hair loss inhibitor | |
| JP3357746B2 (en) | Hair restorer | |
| KR101651248B1 (en) | Cosmetic or pharmaceutical composition for promoting hair growth containing Forsythin | |
| KR100476069B1 (en) | A composition for trichogenousness or preventing the depilation containing 1,2-dithiolthione derivative | |
| KR101569773B1 (en) | Cosmetic or pharmaceutical composition for promoting hair growth containing Artemether | |
| KR101578849B1 (en) | Shampoo or conditioner composition containing Ginsenoside C-Mx1 for promoting hair growth by strengthen the scalp and the hair roots | |
| JP3658758B2 (en) | Hair nourishment, hair growth, hair thickener | |
| CN112915176B (en) | Alpinia katsumadai composition for preventing and treating alopecia | |
| KR20240040151A (en) | Biotin derived compound to treat alopecia | |
| KR101910595B1 (en) | Composition for Treating Hair Loss and Promoting Hair Growth Comprising Terthiophene Derivative | |
| KR102000935B1 (en) | Cosmetic or pharmaceutical composition for promoting hair growth containing 5-hydroxytryptophan | |
| KR102000934B1 (en) | Cosmetic or pharmaceutical composition for promoting hair growth containing Dehydroandrographolide | |
| JP3624318B2 (en) | Hair nourishing agent | |
| KR20150085964A (en) | Cosmetic or pharmaceutical composition for promoting hair growth containing Wogonin | |
| KR101593628B1 (en) | Cosmetic or pharmaceutical composition for promoting hair growth containing breviscapin | |
| KR101618350B1 (en) | Cosmetic or pharmaceutical composition for promoting hair growth containing 5-hydroxytryptophan | |
| KR20150085686A (en) | Cosmetic or pharmaceutical composition for promoting hair growth containing protopanaxadiol | |
| KR20150085963A (en) | Cosmetic or pharmaceutical composition for promoting hair growth containing Protocatechualdehyde |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20211130 |